HST5040 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
245	Propionic acidemia	1
246	Methylmalonic acidemia	1

245. Propionic acidemia

---

Clinical trials : 13 /  Drugs : 16 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 6

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04732429 (ClinicalTrials.gov)	March 15, 2021	21/1/2021	Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia	A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study	Methylmalonic Acidemia;Propionic Acidemia	Drug: HST5040;Drug: Placebo	HemoShear Therapeutics	NULL	Recruiting	2 Years	N/A	All	12	Phase 2	United States;Australia

246. Methylmalonic acidemia

---

Clinical trials : 23 /  Drugs : 31 - (DrugBank : 8) / Drug target genes : 17 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04732429 (ClinicalTrials.gov)	March 15, 2021	21/1/2021	Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia	A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study	Methylmalonic Acidemia;Propionic Acidemia	Drug: HST5040;Drug: Placebo	HemoShear Therapeutics	NULL	Recruiting	2 Years	N/A	All	12	Phase 2	United States;Australia